SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001214659-24-000330
Filing Date
2024-01-05
Accepted
2024-01-05 16:30:27
Documents
12
Period of Report
2024-01-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 o152408k.htm   iXBRL 8-K 26905
  Complete submission text file 0001214659-24-000330.txt   203602

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE alzn-20240105.xsd EX-101.SCH 2991
3 XBRL LABEL FILE alzn-20240105_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE alzn-20240105_pre.xml EX-101.PRE 22343
6 EXTRACTED XBRL INSTANCE DOCUMENT o152408k_htm.xml XML 3514
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 24516664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)